Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yaron Werber
TD

Yaron Werber

TD Cowen
Wall Street Analyst
★★★☆☆
#2263
on 13Foresight · ranked by our own returns
53%
Success Rate
-1.7%
Average Return
59 of 111 calls profitable · -6.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 53% of Yaron Werber's ratings turned a profit when each position was held for 1 year — averaging -1.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

135 Buy 28 Hold 0 Sell
Yaron's Stock Coverage 52 ratings · 2026-11-05
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
EXEL
Exelixis
 Oct 30, 2026 BUY Buy
-34.0% avg upside
34 analysts
$76.00
9.51% Upside
 +1.7% ·
GMAB
Genmab
 Oct 26, 2026 BUY Buy
+22.8% avg upside
28 analysts
$52.00
8.80% Downside
 +27.7% ·
AMGN
Amgen
 Oct 26, 2026 BUY Buy
-29.9% avg upside
57 analysts
$452.00
3.06% Downside
 +3.5% ·
ROIV
Roivant Sciences
 Oct 21, 2026 BUY Strong Buy
+10.7% avg upside
19 analysts
$62.00
68.04% Upside
 +3.9% ·
STOK
Stoke Therapeutics
 Oct 13, 2026 BUY Strong Buy
+55.8% avg upside
18 analysts
$60.00
128.29% Upside
 +17.7% ·
ALEC
Alector
 Oct 05, 2026 HOLD Buy
+370.1% avg upside
15 analysts
 — +11.1% ·
FHTX
Foghorn Therapeutics
 Oct 01, 2026 HOLD Buy
+336.7% avg upside
17 analysts
 — -27.4% ·
ZYME
Zymeworks
 Sep 29, 2026 BUY Strong Buy
+18.4% avg upside
26 analysts
$34.00
18.88% Upside
 +8.3% ·
KLRA
Kailera Therapeutics, Inc.
 Sep 29, 2026 BUY Strong Buy
+249.9% avg upside
5 analysts
$57.00
343.16% Upside
 +15.1% ·
IONS
Ionis Pharmaceuticals
 Sep 23, 2026 BUY Strong Buy
+74.1% avg upside
44 analysts
$84.00
92.92% Upside
 -6.1% ·
RARE
Ultragenyx Pharmaceutical
 Sep 03, 2026 BUY Strong Buy
+193.8% avg upside
36 analysts
$18.00
11.89% Upside
 +15.6% ·
ARGX
Argenx Se
 Aug 17, 2026 BUY Strong Buy
-8.2% avg upside
48 analysts
$1353.00
51.49% Upside
 -9.4% ·
ASND
Ascendis Pharma
 Aug 13, 2026 BUY Strong Buy
+12.3% avg upside
29 analysts
$341.00
35.70% Upside
 +2.8% ·
LEGN
Legend Biotech
 Aug 12, 2026 HOLD Strong Buy
+182.2% avg upside
27 analysts
$24.00
10.95% Upside
 +10.3% ·
SEPN
Septerna, Inc.
 Aug 11, 2026 BUY Strong Buy
+17.7% avg upside
12 analysts
 — -9.6% ·
RLAY
Relay Therapeutics
 Aug 06, 2026 BUY Strong Buy
+22.4% avg upside
22 analysts
 — -13.0% ·
ONC
BeOne Medicines
 Aug 05, 2026 BUY Strong Buy
-1.2% avg upside
29 analysts
$454.00
22.49% Upside
 +18.2% ·
DNTH
Dianthus Therapeutics
 Aug 05, 2026 BUY Strong Buy
+23.4% avg upside
32 analysts
$150.00
82.00% Upside
 -26.2% ·
NUVB
Nuvation Bio
 Jun 01, 2026 BUY Strong Buy
+178.0% avg upside
18 analysts
 — -4.0% ·
JNJ
Johnson & Johnson
 May 18, 2026 BUY Strong Buy
-9.1% avg upside
40 analysts
$226.71
16.94% Downside
 +21.7% ·
JSPR
Jasper Therapeutics
 May 15, 2026 HOLD Strong Buy
+5062.9% avg upside
18 analysts
 — -38.8% ·
UPB
Upstream Bio, Inc.
 May 13, 2026 BUY Strong Buy
+774.9% avg upside
9 analysts
 — -60.5% ·
VOR
Vor Biopharma
 May 13, 2026 BUY Strong Buy
+117.7% avg upside
19 analysts
 — +24.8% ·
PMVP
PMV Pharmaceuticals
 May 12, 2026 BUY Strong Buy
+951.7% avg upside
13 analysts
 — -7.8% ·
CLDX
Celldex
 May 07, 2026 BUY Strong Buy
+42.9% avg upside
28 analysts
 — -15.2% ·
BNTX
BioNTech SE
 May 05, 2026 HOLD Strong Buy
+48.9% avg upside
28 analysts
$94.00
6.57% Upside
 -10.1% ·
PASG
Passage Bio
 Apr 21, 2026 HOLD Buy
+407.3% avg upside
14 analysts
 — -45.1% ·
IOBTQ
IO Biotech
 Mar 31, 2026 HOLD Buy
+4714900.0% avg upside
6 analysts
 — · ·
NKTX
Nkarta
 Mar 26, 2026 BUY Strong Buy
+1080.5% avg upside
16 analysts
 — -26.6% ·
PANW
Palo Alto Networks
 May 21, 2025 BUY Strong Buy
-11.9% avg upside
74 analysts
$230.00
37.19% Downside
 +39.5% ·
GB:0QW0
arGEN X
 Feb 21, 2025 BUY Strong Buy
-23.5% avg upside
25 analysts
$664.00
17.84% Downside
 +17.1% ·
GB:0MGB
Genmab A/S
 Apr 03, 2024 HOLD Buy
-37.4% avg upside
25 analysts
 — -39.3% ·
IMRX
Immuneering
 Mar 14, 2024 HOLD Strong Buy
+379.3% avg upside
12 analysts
 — -44.8% ·
DE:LEG
LEG Immobilien
 Mar 11, 2024 BUY Strong Buy
+96.0% avg upside
18 analysts
 — -6.6% ·
KYNB
Kyntra Bio
 Jun 26, 2023 HOLD Buy
+615.8% avg upside
17 analysts
$3.00
34.37% Downside
 -61.1% ·
TIL
Instil Bio
 Nov 01, 2022 HOLD Buy
+388.9% avg upside
8 analysts
 — -86.1% ·
REGN
Regeneron
 Feb 08, 2021 HOLD Strong Buy
-12.1% avg upside
60 analysts
$565.00
39.06% Downside
 +24.9% ·
OLMA
Olema Pharmaceuticals
 Dec 14, 2020 BUY Strong Buy
+401.3% avg upside
16 analysts
 — -77.5% ·
RCKT
Rocket Pharmaceuticals
 Aug 05, 2020 BUY Buy
+546.4% avg upside
30 analysts
 — +41.7% ·
LRMR
Larimar Therapeutics
 Feb 21, 2020 HOLD Strong Buy
+621.1% avg upside
22 analysts
 — +24.7% ·
WVE
Wave Life Sciences
 Dec 31, 2019 HOLD Strong Buy
+443.6% avg upside
30 analysts
 — -1.9% ·
COGT
Cogent Biosciences
 Aug 12, 2019 HOLD Strong Buy
+24.4% avg upside
26 analysts
 — +30.7% ·
GILD
Gilead Sciences
 Feb 25, 2016 BUY Strong Buy
-27.3% avg upside
66 analysts
$110.00
35.56% Downside
 -20.6% ·
BIIB
Biogen
 Feb 25, 2016 BUY Strong Buy
+6.6% avg upside
53 analysts
$345.00
36.02% Upside
 +8.7% ·
PBYI
Puma Biotechnology
 Sep 03, 2015 BUY Buy
+305.1% avg upside
11 analysts
$94.00
800.36% Upside
 -36.5% ·
AGIO
Agios Pharma
 Feb 18, 2015 HOLD Strong Buy
+99.0% avg upside
30 analysts
$132.00
332.17% Upside
 -66.2% ·
ATRA
Atara Biotherapeutics
 Nov 10, 2014 BUY Buy
+125.8% avg upside
18 analysts
$37.00
361.98% Upside
 · ·
SRPT
Sarepta Therapeutics
 Apr 22, 2014 HOLD Buy
+223.8% avg upside
50 analysts
 — -65.1% ·
RIGL
Rigel
 Jun 04, 2013 HOLD Strong Buy
-47.3% avg upside
17 analysts
$5.00
90.16% Downside
 -12.9% ·
VRTX
Vertex Pharmaceuticals
 Apr 19, 2013 BUY Strong Buy
-20.5% avg upside
62 analysts
$100.00
82.08% Downside
 -25.0% ·
ANTH
Anthera Pharmaceuticals
 Mar 12, 2012 HOLD Buy
+4728471.4% avg upside
9 analysts
$3.00
2999900.07% Upside
 · ·
GSK
GlaxoSmithKline
 Nov 17, 2010 HOLD Hold
-14.7% avg upside
20 analysts
 — +15.9% ·
🔒 47 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yaron Werber — Frequently Asked Questions
How accurate are Yaron Werber's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Yaron's ratings were profitable over a one-year hold, with an average return of -1.6% per rating, or -6.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yaron ranked on 13Foresight?
Yaron Werber is currently ranked #2263 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yaron cover?
Yaron most recently has ratings on EXEL, GMAB, AMGN, ROIV, STOK, ALEC, FHTX, ZYME, KLRA, IONS, RARE, ARGX and 40 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.